

## Pharmaceutical Support

In recent times, Cancer52 has received support from the organisations listed below. We are most grateful for this support.

The table below shows details of the different levels of funding that were received in Cancer52's financial year from 1<sup>st</sup> April 2021 to 31<sup>st</sup> March 2022.

Organisation	Level of Support	Details of funding
• Abbvie	• £10,000	• Corporate Supporters Programme
• BMS	• £10,000	• Corporate Supporters Programme
• Gilead	• £10,000	• Corporate Supporters Programme
• GSK	• £10,000	• Corporate Supporters Programme
• Ipsen	• £10,000	• Corporate Supporters Programme
• Roche	• £6,666 • £10,000	• Corporate Supporters Programme 2021 (part year) • Corporate Supporters Programme 2022
• Sanofi	• £10,000	• Corporate Supporters Programme
• Takeda	• £10,000	• Corporate Supporters Programme

The table below shows details of project specific funding that has been received to date in Cancer52's financial year from 1<sup>st</sup> April 2022.

Organisation	Level of Support	Details of funding
• Ipsen	• £11,990	• Project Specific Funding
• Pfizer	• £10,900	• Project Specific Funding